Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032000 | 0.94 | CCR5 (0.84) | CCR5CHRM1HTR2A | |
| SCHEMBL12207016 | 0.90 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6339869 | 0.89 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6336926 | 0.89 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6705208 | 0.87 | CCR5 (1.00) | CCR5CHRM1HTR2A | |
| Hydrochloric Acid SCHEMBL6702225 | 0.87 | CCR5 (0.98) | CCR5CHRM1HTR2A | |
| SCHEMBL6336797 | 0.86 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6703811 | 0.85 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6337380 | 0.85 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6700385 | 0.85 | CCR5 (0.91) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547789-B2 | Process for the preparation of N-(4-piperidinyl)-N-ethyl-phenylacetamides from N-Boc-4-oxopiperidine | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| US-20080214824-A1 | Process for the Preparation of N-(4-Piperidinyl)-N-Ethyl-Phenylacetamides from N-Boc-4-Oxopiperidine | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1828128-A1 | PROCESS FOR THE PREPARATION OF N-(4-PIPERIDINYL)-N-ETHYL-PHENYLACETAMIDES FROM N-BOC-4-OXOPIPERIDINE | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064221-A1 | PROCESS FOR THE PREPARATION OF N- (4-PIPERIDINYL) -N-ETHYL-PHENYLACETAMIDES FROM N-BOC-4-OXOPIPERIDINE | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214824-A1 | Process for the Preparation of N-(4-Piperidinyl)-N-Ethyl-Phenylacetamides from N-Boc-4-Oxopiperidine | NISCH, NPPA, AZI2 | CCR5 1084/4885CHRM1 278/4885HTR2A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.